UY25825A1 - Procedimiento para preparar derivados de indol - Google Patents
Procedimiento para preparar derivados de indolInfo
- Publication number
- UY25825A1 UY25825A1 UY25825A UY25825A UY25825A1 UY 25825 A1 UY25825 A1 UY 25825A1 UY 25825 A UY25825 A UY 25825A UY 25825 A UY25825 A UY 25825A UY 25825 A1 UY25825 A1 UY 25825A1
- Authority
- UY
- Uruguay
- Prior art keywords
- indol
- procedure
- preparing derivatives
- hydrobromide
- preparing
- Prior art date
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- -1 (1-methylpyrrolidin-2 (R) -yl) methyl Chemical group 0.000 abstract 1
- BORDVONYOHPTGR-JQDLGSOUSA-N 5-[2-(benzenesulfonyl)ethyl]-3-[[(2r)-1-methylpyrrolidin-2-yl]methyl]-1h-indole;hydrate;hydrobromide Chemical compound O.[Br-].C[N@H+]1CCC[C@@H]1CC(C1=C2)=CNC1=CC=C2CCS(=O)(=O)C1=CC=CC=C1 BORDVONYOHPTGR-JQDLGSOUSA-N 0.000 abstract 1
- 206010059245 Angiopathy Diseases 0.000 abstract 1
- 206010013654 Drug abuse Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 206010019233 Headaches Diseases 0.000 abstract 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 231100000869 headache Toxicity 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Electroluminescent Light Sources (AREA)
- Lasers (AREA)
Abstract
La presente invención proporciona un procedimiento para preparar bromhidrato de eletriptán monohidratado de fórmula (I) Este compuesto es el bromhidrato de eletripán anhidro: 3-((1-metilpirrolidin-2(R)-il)metil)-5-82-fenilsulfoniletil)-1H-indol, estr clasificado como un agonista receptor 5-HTIB/Id y es de particular utilidad en el tratamiento de la migrana, También puede utilizarse para tratar hipertensión, depresión, hemesis, trastornos de alimentación, abusos de fármacos, dolor, cefalea asociada a un trastorno vascular.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9825988.0A GB9825988D0 (en) | 1998-11-27 | 1998-11-27 | Indole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY25825A1 true UY25825A1 (es) | 2000-08-21 |
Family
ID=10843140
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25823A UY25823A1 (es) | 1998-11-27 | 1999-11-29 | Derivados de indol y su uso en el tratamiento de la migrana |
| UY25825A UY25825A1 (es) | 1998-11-27 | 1999-11-30 | Procedimiento para preparar derivados de indol |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25823A UY25823A1 (es) | 1998-11-27 | 1999-11-29 | Derivados de indol y su uso en el tratamiento de la migrana |
Country Status (53)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0018968D0 (en) * | 2000-08-02 | 2000-09-20 | Pfizer Ltd | Particulate composition |
| JP2006522790A (ja) | 2003-04-11 | 2006-10-05 | ファイザー・インク | エレトリプタンと重炭酸ナトリウムを含む医薬組み合わせ物 |
| US6927296B2 (en) | 2003-07-23 | 2005-08-09 | Pfizer Inc. | Process |
| GB0317229D0 (en) * | 2003-07-23 | 2003-08-27 | Pfizer Ltd | Improved process |
| EP2093225A1 (en) | 2007-05-01 | 2009-08-26 | Plus Chemicals B.V. | Process for preparing crystalline eletriptan hydrobromide form ß |
| EP2038273A1 (en) * | 2007-05-29 | 2009-03-25 | Plus Chemicals B.V. | A process for preparing 5-bromo-3-[(r)-1-methyl-pyrrolidin-2-ylmethyl]-1h-indole |
| EP2225224A2 (en) * | 2007-12-17 | 2010-09-08 | Actavis Group PTC EHF | Novel hemioxalate salt of eletriptan |
| WO2010097703A1 (en) * | 2009-02-25 | 2010-09-02 | Actavis Group Ptc Ehf | Highly pure eletriptan or a pharmaceutically acceptable salt thereof substantially free of eletriptan n-oxide impurity |
| WO2010116386A2 (en) * | 2009-04-08 | 2010-10-14 | Biophore India Pharmaceuticals Pvt. Ltd. | Novel polymorph of eletriptan hydrobromide and process for the preparation thereof |
| US8754239B2 (en) | 2010-01-19 | 2014-06-17 | Sms Pharmaceuticals Limited | Process for preparing eletriptan hydrobromide having α-form |
| WO2014063752A1 (en) | 2012-10-26 | 2014-05-01 | Synthon Bv | Process for making crystalline form alpha of eletriptan hydrobromide |
| CN103893112A (zh) * | 2012-12-31 | 2014-07-02 | 重庆圣华曦药业股份有限公司 | 氢溴酸依来曲普坦注射液 |
| CN107954947A (zh) * | 2016-10-14 | 2018-04-24 | 北京莱瑞森医药科技有限公司 | 沃替西汀氢溴酸盐晶型c及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3952741A (en) * | 1975-01-09 | 1976-04-27 | Bend Research Inc. | Controlled release delivery system by an osmotic bursting mechanism |
| FR2624732B1 (fr) * | 1987-12-21 | 1991-02-15 | Synthelabo | Formulation pharmaceutique a liberation prolongee |
| US5474784A (en) * | 1990-03-02 | 1995-12-12 | British Technology Group Limited | Dispensing device |
| HUT64326A (en) | 1990-10-15 | 1993-12-28 | Pfizer | Process for production indole derivatives and pharmaceutical preparations containing these compounds |
| US5545644A (en) * | 1990-10-15 | 1996-08-13 | Pfizer Inc. | Indole derivatives |
| US5464633A (en) * | 1994-05-24 | 1995-11-07 | Jagotec Ag | Pharmaceutical tablets releasing the active substance after a definite period of time |
| GB9417310D0 (en) * | 1994-08-27 | 1994-10-19 | Pfizer Ltd | Therapeutic agents |
| GB9510223D0 (en) * | 1995-05-20 | 1995-07-19 | Pfizer Ltd | Therapeutic agent |
| TW448172B (en) * | 1996-03-08 | 2001-08-01 | Pharmacia & Upjohn Co Llc | Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation |
| US5998462A (en) * | 1996-12-16 | 1999-12-07 | Allelix Biopharmaceuticals Inc. | 5-alkyl indole compounds |
| GB9704498D0 (en) * | 1997-03-05 | 1997-04-23 | Glaxo Wellcome Spa | Chemical compound |
| TR199903332T2 (xx) | 1997-07-03 | 2000-09-21 | Pfizer Inc. | Eletriptan hemis�lfat ve kafein i�eren farmas�tikal bile�ikler. |
-
1998
- 1998-11-27 GB GBGB9825988.0A patent/GB9825988D0/en not_active Ceased
-
1999
- 1999-01-11 UA UA2001053569A patent/UA68402C2/uk unknown
- 1999-11-01 OA OA1200100103A patent/OA11671A/en unknown
- 1999-11-01 TR TR2001/01493T patent/TR200101493T2/xx unknown
- 1999-11-01 IL IL14166399A patent/IL141663A/en not_active IP Right Cessation
- 1999-11-01 AP APAP/P/2001/002149A patent/AP2001002149A0/en unknown
- 1999-11-01 SK SK699-2001A patent/SK285774B6/sk unknown
- 1999-11-01 ID IDW00200101132A patent/ID28802A/id unknown
- 1999-11-01 BR BR9915692-0A patent/BR9915692A/pt not_active Application Discontinuation
- 1999-11-01 AU AU62253/99A patent/AU754731B2/en not_active Ceased
- 1999-11-01 HK HK02104379.1A patent/HK1042898B/zh not_active IP Right Cessation
- 1999-11-01 GE GEAP19995913A patent/GEP20043183B/en unknown
- 1999-11-01 AT AT99949292T patent/ATE273300T1/de not_active IP Right Cessation
- 1999-11-01 HR HR20010398 patent/HRP20010398B1/xx not_active IP Right Cessation
- 1999-11-01 PL PL99347928A patent/PL194503B1/pl unknown
- 1999-11-01 JP JP2000585231A patent/JP3777094B2/ja not_active Expired - Fee Related
- 1999-11-01 RS YUP-188/01A patent/RS50002B/sr unknown
- 1999-11-01 CN CN998135798A patent/CN1131860C/zh not_active Expired - Fee Related
- 1999-11-01 EP EP99949292A patent/EP1135381B1/en not_active Expired - Lifetime
- 1999-11-01 EA EA200100297A patent/EA003551B1/ru not_active IP Right Cessation
- 1999-11-01 DK DK99949292T patent/DK1135381T3/da active
- 1999-11-01 NZ NZ510055A patent/NZ510055A/en unknown
- 1999-11-01 CZ CZ20011839A patent/CZ295472B6/cs not_active IP Right Cessation
- 1999-11-01 WO PCT/IB1999/001754 patent/WO2000032589A1/en not_active Ceased
- 1999-11-01 EE EEP200100285A patent/EE04914B1/xx not_active IP Right Cessation
- 1999-11-01 ES ES99949292T patent/ES2224701T3/es not_active Expired - Lifetime
- 1999-11-01 PT PT99949292T patent/PT1135381E/pt unknown
- 1999-11-01 CA CA002352392A patent/CA2352392C/en not_active Expired - Fee Related
- 1999-11-01 HU HU0105308A patent/HUP0105308A3/hu unknown
- 1999-11-01 SI SI9930633T patent/SI1135381T1/xx unknown
- 1999-11-01 KR KR10-2001-7006605A patent/KR100413739B1/ko not_active Expired - Fee Related
- 1999-11-01 DE DE69919388T patent/DE69919388T2/de not_active Expired - Fee Related
- 1999-11-02 TW TW088119069A patent/TWI246512B/zh not_active IP Right Cessation
- 1999-11-09 HN HN1999000196A patent/HN1999000196A/es unknown
- 1999-11-18 PA PA19998485701A patent/PA8485701A1/es unknown
- 1999-11-23 PE PE1999001178A patent/PE20001299A1/es not_active Application Discontinuation
- 1999-11-24 DZ DZ990248A patent/DZ2948A1/xx active
- 1999-11-24 CO CO99074057A patent/CO5150178A1/es unknown
- 1999-11-24 TN TNTNSN99221A patent/TNSN99221A1/fr unknown
- 1999-11-24 GC GCP1999381 patent/GC0000113A/xx active
- 1999-11-24 MA MA25854A patent/MA26708A1/fr unknown
- 1999-11-25 AR ARP990106025A patent/AR024232A1/es not_active Application Discontinuation
- 1999-11-25 MY MYPI99005153A patent/MY124078A/en unknown
- 1999-11-26 GT GT199900202A patent/GT199900202A/es unknown
- 1999-11-26 SV SV1999000204A patent/SV1999000204A/es not_active Application Discontinuation
- 1999-11-29 US US09/450,462 patent/US20020013358A1/en not_active Abandoned
- 1999-11-29 UY UY25823A patent/UY25823A1/es unknown
- 1999-11-30 UY UY25825A patent/UY25825A1/es unknown
-
2001
- 2001-02-27 IS IS5868A patent/IS2238B/is unknown
- 2001-03-13 CU CU20010065A patent/CU23269A3/es unknown
- 2001-03-14 CR CR6325A patent/CR6325A/xx not_active Application Discontinuation
- 2001-04-02 ZA ZA200102681A patent/ZA200102681B/xx unknown
- 2001-05-23 BG BG105539A patent/BG64706B1/bg unknown
- 2001-05-25 NO NO20012584A patent/NO320798B1/no unknown
-
2003
- 2003-02-27 US US10/376,385 patent/US7238723B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY25825A1 (es) | Procedimiento para preparar derivados de indol | |
| BR9206810A (pt) | Derivados de indol | |
| LU92692I2 (fr) | Ibrutinib, ou un sel pharmaceutiquement acceptablede celui-ci | |
| RU94045897A (ru) | Производные индола в качестве 5-hti-агонистов, фармацевтическая композиция и способ лечения | |
| LU91407I2 (fr) | Sunitinib optionnellement sous la forme d'un sel pharmaceutiquement acceptable y compris le sel l-malate (sutent) | |
| EE05036B1 (et) | Asendatud indoolid NFkB aktiivsuse moduleerimiseks, nende valmistamismeetod ja kasutamine ning ravim ja selle valmistamismeetod | |
| MX337817B (es) | Pirazolo [1,5-a] pirimidinas de utilidad como inhibidores de proteina quinasas. | |
| BR9306012A (pt) | Derivados de indóis como antagonistas 5-ht1 | |
| TW200613306A (en) | Imidazotriazines as protein kinase inhibitors | |
| MY128370A (en) | Pyrrolotriazane inhibitors of kinases | |
| MY126235A (en) | 3-(4-amidopyrrol-2-ylmethylidene) -2- indolinone derivatives as protein kinase inhibitors. | |
| DE69400824D1 (de) | Indol-derivate als 5-ht1-ähnliche antagonisten zur behandlung von migräne | |
| RU95109927A (ru) | Производные 5-арилиндола и их применение в качестве агонистов серотонина (5-ht*00i) | |
| CO4950530A1 (es) | Agonistas de receptores 5-ht, y metoclopramida para el tratamiento de la migrana | |
| MXPA05007115A (es) | Nuevos agonistas inversos del receptor cb 1. | |
| Cohen et al. | 5-Hydroxytryptamine1F receptors do not participate in vasoconstriction: lack of vasoconstriction to LY344864, a selective serotonin1F receptor agonist in rabbit saphenous vein | |
| ATE224388T1 (de) | Indolderivate zur behandlung von migräne | |
| EA200301221A1 (ru) | Лечение расстройств с гиперактивностью и дефицитом внимания | |
| MX9708966A (es) | Sal fumarato de pirrolidinil metil indol, composicion que la contiene, procedimiento para su preparacion y uso de la misma. | |
| RU2019135609A (ru) | Комбинация антагониста 5-ht6-рецептора и ингибитора ацетилхолинэстеразы для применения при лечении болезни альцгеймера у субпопуляции пациентов, которые являются носителями аллелей apoe4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ABAN | Application deemed to be withdrawn (no publication fee paid) |
Effective date: 20090309 |